| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A case treated with Crizotinib after secondary MET amplification of A double Rare L747S and G719S EGFR mutation Pulmonary Sarcomatoid Carcinoma
|
He, Q.
|
|
|
31 |
4 |
p. 544-546
|
artikel
|
| 2 |
A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland
|
Panje, C.M.
|
|
|
31 |
4 |
p. 501-506
|
artikel
|
| 3 |
Adjuvant therapy for colorectal cancer in 2020: has anything changed this millennium?
|
Bridgewater, J.
|
|
|
31 |
4 |
p. 447-448
|
artikel
|
| 4 |
Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance)
|
Lee, H.
|
|
|
31 |
4 |
p. 487-494
|
artikel
|
| 5 |
Corrigendum to An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45
|
Bjelic-Radisic, V.
|
|
|
31 |
4 |
p. 552
|
artikel
|
| 6 |
Corrigendum to Cancer, mental health and end of life simulation (CAMhELS): A novel effectiveness evaluation
|
Fernando, A.
|
|
|
31 |
4 |
p. 548
|
artikel
|
| 7 |
Corrigendum to Difference of PDT induced apoptotic gene expression in 2D and 3D nasopharyngeal carcinoma cell Models
|
Wu, R.W.K.
|
|
|
31 |
4 |
p. 551
|
artikel
|
| 8 |
Corrigendum to Investigate the efficacy of Photodynamic Therapy on nasopharyngeal carcinoma multicellular tumor spheroids
|
Wu, R.W.
|
|
|
31 |
4 |
p. 549
|
artikel
|
| 9 |
Corrigendum to Overview of the relevance of PI3K pathway in HR-positive breast cancer
|
Vasan, N.
|
|
|
31 |
4 |
p. 547
|
artikel
|
| 10 |
Corrigendum to Photodynamic therapy induced apoptosis and autophagy in 2D and 3D nasopharyngeal carcinoma cell models
|
Wu, R.W.K.
|
|
|
31 |
4 |
p. 550
|
artikel
|
| 11 |
Editorial Board
|
|
|
|
31 |
4 |
p. iii
|
artikel
|
| 12 |
Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials
|
Chalabi, M.
|
|
|
31 |
4 |
p. 525-531
|
artikel
|
| 13 |
Epigenetic modulations and lineage plasticity in advanced prostate cancer
|
Ge, R.
|
|
|
31 |
4 |
p. 470-479
|
artikel
|
| 14 |
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database
|
Salem, M.E.
|
|
|
31 |
4 |
p. 480-486
|
artikel
|
| 15 |
First birth achieved after fertility preservation using vitrification of in vitro matured oocytes in a woman with breast cancer
|
Grynberg, M.
|
|
|
31 |
4 |
p. 541-542
|
artikel
|
| 16 |
Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma
|
Lin, G.
|
|
|
31 |
4 |
p. 517-524
|
artikel
|
| 17 |
Hepatocellular carcinoma—united forces against a global killer
|
Lordick, F.
|
|
|
31 |
4 |
p. 449-450
|
artikel
|
| 18 |
Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients
|
Algazi, A.
|
|
|
31 |
4 |
p. 532-540
|
artikel
|
| 19 |
Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)
|
Metaxas, Y.
|
|
|
31 |
4 |
p. 495-500
|
artikel
|
| 20 |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
|
Park, Y.H.
|
|
|
31 |
4 |
p. 451-469
|
artikel
|
| 21 |
Solid organ transplant rejection associated with immune-checkpoint inhibitors
|
Saberianfar, S.
|
|
|
31 |
4 |
p. 543-544
|
artikel
|
| 22 |
Table of Contents
|
|
|
|
31 |
4 |
p. i-ii
|
artikel
|
| 23 |
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
|
Oxnard, G.R.
|
|
|
31 |
4 |
p. 507-516
|
artikel
|
Tijdschrift beschrijving